Literature DB >> 22190283

Multivariate analysis of several molecular markers and clinicopathological features in postoperative prognosis of hepatocellular carcinoma.

Qiang Zuo1, Hui Huang, Min Shi, Futing Zhang, Jiping Sun, Jianping Bin, Yulin Liao, Wangjun Liao.   

Abstract

This study was designed to assess the impact of several molecular markers and clinicopathological characteristics on postoperative survival of patients with hepatocellular carcinoma (HCC). Postoperative clinical data of 64 patients with HCC were retrospectively analyzed. K-ras, PIK3CA, and BRAF gene mutations in surgically resected specimens of the 64 patients with HCC were detected by pyrosequencing. H-ras and XB130 protein expression was examined by immunohistochemistry. A Cox proportional hazards regression model was used for univariate and multivariate survival analyses of the clinical and pathological parameters. The mutation rates of K-ras, PIK3CA, and BRAF genes in HCC were found to be 4.69%, 1.56%, and 0%, respectively. Positive expression rate of XB130 and H-ras in HCC was 75.0% and 93.8%, respectively. Univariate analysis revealed that clinicopathological factors impacting postoperative prognosis of patients with HCC include clinical stage, tumor diameter, and postoperative transcatheter arterial embolization therapy for HCC. Meanwhile, multivariate analysis showed that clinical stage (relative risk [RR]: 6.420, P = 0.013) and tumor diameter (RR: 1.498, P = 0.014) were independent factors impacting postoperative survival of patients with HCC. These findings indicate that the clinical stage and tumor diameter are independent risk factors impacting postoperative survival of patients with HCC. Gene mutations of K-ras and PIK3CA and protein expression of XB130 and H-ras are not associated with the postoperative prognosis of patients with HCC.
Copyright © 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22190283     DOI: 10.1002/ar.21531

Source DB:  PubMed          Journal:  Anat Rec (Hoboken)        ISSN: 1932-8486            Impact factor:   2.064


  16 in total

1.  XB130 expression in human osteosarcoma: a clinical and experimental study.

Authors:  Xiaohui Wang; Ruiguo Wang; Zhaolong Liu; Fengyun Hao; Hai Huang; Wenchen Guo
Journal:  Int J Clin Exp Pathol       Date:  2015-03-01

2.  Expression of XB130 in human ductal breast cancer.

Authors:  Jiacun Li; Wanli Sun; Hui Wei; Xiurong Wang; Hongjun Li; Zhengjun Yi
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

3.  Targeting the Ras/Raf/MEK/ERK pathway in hepatocellular carcinoma.

Authors:  Sufang Yang; Guohua Liu
Journal:  Oncol Lett       Date:  2017-01-02       Impact factor: 2.967

Review 4.  Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma: Monotherapies and Combined Therapies.

Authors:  Tao Ouyang; Xuefeng Kan; Chuansheng Zheng
Journal:  Front Oncol       Date:  2022-06-16       Impact factor: 5.738

5.  Study of the correlation between H-ras mutation and primary hepatocellular carcinoma.

Authors:  Guode Sui; Xuexiao Ma; Shiguo Liu; Haitao Niu; Qian Dong
Journal:  Oncol Lett       Date:  2012-07-27       Impact factor: 2.967

6.  XB130: A novel adaptor protein in cancer signal transduction.

Authors:  Ruiyao Zhang; Jingyao Zhang; Qifei Wu; Fandi Meng; Chang Liu
Journal:  Biomed Rep       Date:  2016-02-01

Review 7.  XB130-A Novel Adaptor Protein: Gene, Function, and Roles in Tumorigenesis.

Authors:  Xiao-Hui Bai; Hae-Ra Cho; Serisha Moodley; Mingyao Liu
Journal:  Scientifica (Cairo)       Date:  2014-06-05

8.  XB130 deficiency affects tracheal epithelial differentiation during airway repair.

Authors:  Jinbo Zhao; Yingchun Wang; Andrew Wakeham; Zhenyue Hao; Hiroaki Toba; Xiaohui Bai; Shaf Keshavjee; Tak W Mak; Mingyao Liu
Journal:  PLoS One       Date:  2014-10-01       Impact factor: 3.240

9.  Downregulation of HBx Restrains Proliferation, Migration, and Invasion of HepG2 Cells.

Authors:  Chaoqun Huang; Wei Liu; Xiaochuan Zhao; Libin Zhao; Fuxiang Wang
Journal:  Anal Cell Pathol (Amst)       Date:  2021-05-13       Impact factor: 2.916

10.  Prognostic significance of XB130 expression in surgically resected pancreatic ductal adenocarcinoma.

Authors:  Jianli Zhang; Xiuli Jiang; Jian Zhang
Journal:  World J Surg Oncol       Date:  2014-03-01       Impact factor: 2.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.